Michael Hufford
@MichaelHufford
Followers
276
Following
455
Media
3
Statuses
80
Entrepreneur, drug developer, researcher, carpenter and guitar player, in decreasing order of talent (with a serious drop-off after #3)
Pittsburgh, PA
Joined July 2011
Today, the FDA approved another over the counter naloxone nasal spray product – a medicine that reverses opioid overdoses and saves lives. Beating the opioid and overdose epidemic is a core pillar of my Unity Agenda. My Administration has committed unprecedented resources to
3K
2K
7K
Over-the-counter Narcan will save lives, experts say. But the cost will affect access
1
4
7
Morphoceuticals is pleased to announce our seed funding for our programs using electroceuticals in limb regeneration and amputation stump health. https://t.co/lQnfYOIMFt
bizjournals.com
Human limb and organ regeneration seems like the stuff of science fiction. But in the labs of Tufts University professors Michael Levin and David Kaplan, it’s becoming a reality.
5
12
101
Many cell therapy approaches require genetic engineering that reprograms cells to fight a specific disease. Conversely, our allogeneic cell therapy platform does not involve genetic engineering, simplifying the regulatory and commercial pathway. #CellTherapy
0
1
12
OTC nalxone is one step closer... @Surgeon_General @DrCaliff_FDA @POTUS @ScottGottliebMD @ZachWritesStuff @maiasz @nabarund
https://t.co/vPQisuNHkA
1
2
7
We are developing a pipeline of allogeneic cell therapies. Our platform leverages the lymph node as an in vivo bioreactor to grow functioning ectopic organs. #LymphNode #DrugDiscovery #Type1Diabetes #TissueRegeneration #OrganRegeneration #RegenerativeMedicine #cell #Allogeneic
1
5
14
A review of our recent progress using our cell therapy platform @LyGenesis_Inc to regenerate organs...
technologyreview.com
A volunteer with severe liver disease will soon undergo a procedure that could lead them to grow a second liver.
0
0
7
Harm Reduction Therapeutics' Phase 1 clinical trial met its primary endpoints -- this successful milestone triggers work on a new drug application of a low cost, over-the-counter (OTC) intranasal naloxone product for FDA to review
prnewswire.com
/PRNewswire/ -- Harm Reduction Therapeutics (HRT), a 501c3 nonprofit pharmaceutical company, announced today positive results from its pivotal Phase 1 clinical...
0
3
3
Prometheus Unbound: From Myth to the Clinical Reality of Organ Regeneration. Check out CEO, Michael Hufford's, talk at this years Investing in the Age of Longevity Conference https://t.co/CWUNtK9nyG
0
2
8
Next we’re joined by @michaelhufford, CEO and co-founder of #LeGenesis as he discusses ‘Prometheus Unbound: From Myth to the Clinical Reality of Organ Regeneration’. #MILongevity #LongevityWeek
0
1
4
LyGenesis adds inborn #metabolism errors to drug pipeline... #LyGenesis adds orphan paediatric indications to its drug development pipeline with novel approach for treating patients with Maple syrup urine disease. #longevity #MSUD @MichaelHufford #liver
https://t.co/DIba1lqvT5
0
1
4
This week on #TheIncrementalist Grow Your Own Organs, with @MichaelHufford, CEO Lygenesis; discussion includes using the bodies own bio-reactor (lymph nodes) to grow replacement liver, recent FDA clearance to proceed to human trials, and more https://t.co/eUCUAjgpLU
0
1
2
An important and thoughtful take on the tragic implications of our collective inability to reign in the costs of life-saving naloxone...
filtermag.org
When I walk into my local pharmacy to pick up a naloxone kit, I don’t need to present a prescription. ...
0
2
4
What have we learned from setbacks and how to move the field forward post-COVID Hear from @MichaelHufford Maddalena Adorno Dorian Therapeutics Natalia Novac @LillyPad Wed 5th May 1600 BST Register for free https://t.co/N4PCP2jIDz Part of the #Longevity Leaders Congress #ageing
0
1
3
A busy and productive year. Next up, a Phase 2a clinical trial of our cell therapy for patients with end stage liver disease...
prnewswire.com
/PRNewswire/ -- LyGenesis, Inc., a biotechnology company developing cell therapies that enable organ regeneration, announced today that the U.S Food and Drug...
1
0
1
So, we are keeping busy... LyGenesis announced today that 4 peer-reviewed papers have been published on our organ regeneration technology. Next up, a clinical trial for patients with end stage liver disease https://t.co/NNqwa3LYoi
#youcangrowwhatwhere
prnewswire.com
/PRNewswire/ -- LyGenesis, Inc., a biotechnology company focused on regenerative medicine, announced today that four peer-reviewed papers have been published...
0
0
8
“It’s worth pointing out just how remarkable this is.” #LyGenesis’ @MichaelHufford talks #Longevity #research programmes and #investment. #FirstLongevity
https://t.co/5VLlUjdcND
1
1
1
#FirstLongevity: More #news from us, as we announce our premier league Advisory Panel... #Longevity #longevitynews
https://t.co/VwvvOxn163
@aubreydegrey @gbpalantir @jpsenescence @DeepTech2_0 @MorleyLorraine @RealMargaretta @MichaelHufford @geochurch @biogerontology
0
3
6
@MichaelHufford of Lygenesis speaking on "From Science Fiction to FDA Submission: Ectopic Organoids and the Commercialization of Regenerative Medicine" at #Longevity2020
https://t.co/IuryP3UfBW
0
1
1